Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton’s antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer.
In the study, Enlyton’s targeting agent increasingly localized in tumor, while 18F-FDG did not. 18F-FDG also exhibited the tendency to localize in normal tissues. Dr. Edward Martin Jr. (Enlyton CSO and Professor of Surgery at The Ohio State University) said, “We are excited with the results of the study and the potential it offers for successful use of our cancer-specific targeting agent in clinical trials for preoperative, intraoperative, and postoperative PET-based imaging of colorectal cancer.”
“124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results”
The study, entitled, “124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results,” was published in the World Journal of Surgical Oncology (2010, 8:65) by Zou, Povoski, Hall, Carlton, Hinkle, Xu, Mojzisik, Johnson, Knopp, Martin, and Sun, authors from Enlyton, Ltd., The Ohio State University, and The University of Michigan.